Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 411Lymphoma 304Carcinoma, Non-Small-Cell Lung 262Melanoma 255Precursor Cell Lymphoblastic Leukemia-Lymphoma 251Prostatic Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 242Leukemia, Myeloid, Acute 222Lung Neoplasms 215Neoplasms 209Colonic Neoplasms 209Lymphoma, Non-Hodgkin 207Lymphoma, Large B-Cell, Diffuse 204Leukemia 200Multiple Myeloma 197Lymphoma, Follicular 197Colorectal Neoplasms 190Rectal Neoplasms 188Ovarian Neoplasms 184Burkitt Lymphoma 179Brain Neoplasms 171Neoplasm Metastasis 166Lymphoma, Mantle-Cell 163Carcinoma, Renal Cell 163Glioblastoma 161Sarcoma 156Pancreatic Neoplasms 147Lymphoma, B-Cell, Marginal Zone 143Unspecified Adult Solid Tumor, Protocol Specific 138Gliosarcoma 133

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Interventional × Urachal adenocarcinoma × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡